STRN3 and gastric cancer: Additionally, the STRN3-derived Hippo-activating peptide (SHAP), designed to target the PP2Aa–STRN3 interaction region, has demonstrated the restoration of Hippo activity and reduced gastric cancer tumour size in xenograft mouse models [79].